Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544687 | 0.89 | EGFR (0.43) | EGFRTYK2CCNT1CDK9 | |
| SCHEMBL29545545 | 0.89 | EGFR (0.45) | EGFRTYK2CCNE2CDK4CCND1 | |
| SCHEMBL29544823 | 0.89 | EGFR (0.46) | EGFRTYK2 | |
| SCHEMBL29544947 | 0.89 | TYK2 (0.45) | EGFRTYK2 | |
| SCHEMBL29545632 | 0.88 | EGFR (0.46) | EGFRTYK2CCNT1CDK9 | |
| SCHEMBL29544462 | 0.87 | TYK2 (0.42) | EGFRTYK2 | |
| SCHEMBL29544860 | 0.87 | EGFR (0.49) | EGFR | |
| SCHEMBL29544852 | 0.87 | EGFR (0.49) | EGFR | |
| SCHEMBL29545225 | 0.86 | EGFR (0.47) | EGFRTYK2CCNT1CDK9 | |
| SCHEMBL29544775 | 0.85 | EGFR (0.47) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |